Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


Pharma

Pharmaceutical Global Development

APR IS engaged in the research, development, and licensing of added value, technology driven and clinically proven prescription pharmaceuticals.

The innovative business approach based on an integrated vision of technologies available and market opportunities enables APR to select and in-license innovation opportunities or develop internally the whole cycle of research&development bringing to fruition innovative product deliveries to improve patients quality of life.

APR files and obtains worldwide market approval and sells them through an established network of commercial partners globally.




Search results